Press Releases

Date Title
Toggle Summary vTv Therapeutics Announces Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diabetes
TTP399, a novel glucokinase activator shows statistically significant reduction in HbA1c without increases in ketones or hypoglycemia HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 6, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced positive results from the primary analysis of Part 1 of the
View HTML
Toggle Summary vTv Therapeutics Announces 2019 First Quarter Financial Results and Update
HIGH POINT, N.C. --(BUSINESS WIRE)--May 1, 2019-- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter that ended March 31, 2019 , and provided an update on recent achievements and upcoming events. “We continue to make significant progress with our operational
View HTML
Toggle Summary vTv Therapeutics to Present at the 14th International Conference on Alzheimer’s & Parkinson’s Diseases
Presentation of Results for Subgroup of Patients with Mild Alzheimer’s Disease and Type 2 Diabetes in the STEADFAST Study HIGH POINT, N.C. --(BUSINESS WIRE)--Mar. 28, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of
View HTML
Toggle Summary vTv Therapeutics Announces $15 Million of Class A Common Stock Financings
Proceeds Will Fund Start-Up Activities for Current and Future Clinical Trials HIGH POINT, N.C. --(BUSINESS WIRE)--Mar. 18, 2019-- vTv Therapeutics Inc. (Nasdaq:VTVT) (the “Company”) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase
View HTML
Toggle Summary vTv Therapeutics Announces 2018 Fourth Quarter and Full Year Financial Results and Update
HIGH POINT, N.C. --(BUSINESS WIRE)--Feb. 27, 2019-- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the fourth quarter and year that ended December 31, 2018 , and provided an update on recent achievements and upcoming events. “We are excited about the therapeutic potential
View HTML
Toggle Summary vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study
Results Found TTP399 Demonstrated a Statistically Significant Improvement in HbA1c Compared to Placebo without Hypoglycemia or Hyperlipidemia HIGH POINT, N.C. --(BUSINESS WIRE)--Jan. 16, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the publication of a paper in Science Translational
View HTML
Toggle Summary vTv Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 19, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that company management will present a corporate overview at the Piper Jaffray 30 th Annual Healthcare Conference on Tuesday, Nov. 27, 2018 at 2:10 p.m. ET in New York City .
View HTML
Toggle Summary vTv Therapeutics Announces Third Quarter 2018 Results and Update
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 8, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT) today reported financial results for the third quarter that ended September 30, 2018 , and provided an update on recent achievements and upcoming events. “We continue to believe in the therapeutic potential of
View HTML
Toggle Summary vTv Therapeutics Announces Transfer of Listing to The Nasdaq Capital Market
HIGH POINT, N.C. --(BUSINESS WIRE)--Oct. 29, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease (AD) and diabetes, today announced that The NASDAQ Stock Market LLC
View HTML
Toggle Summary vTv Therapeutics Presents Positive Data on the Effect of Azeliragon in Patients with Alzheimer’s and Diabetes at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Subgroup Analysis Indicates Potential Benefit of Treatment with Azeliragon for Patients with Type 2 Diabetes and Alzheimer’s Disease Nearly 40 percent of Medicare Beneficiaries with Dementia Also Suffer from Diabetes, a Large Population to Potentially Benefit HIGH POINT, N.C.
View HTML